Short answer
Arbutus Biopharma Corp (ABUS) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $299,000 (down 43.5% year over year) with net income of $59M.
Q3 2026 key financials · XBRL
- Revenue
- $299,000
- −43.5% YoY · −70.5% QoQ
- Net income
- $59M
- +863.6% YoY · +1249.4% QoQ
- Operating margin
- -3509.7%
- EPS (diluted)
- $0.29
- +825.0% YoY · +1066.7% QoQ
Source: XBRL data from the Arbutus Biopharma Corp (ABUS) Q3 2026 10-Q on SEC EDGAR. USD.
Arbutus Biopharma Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $13.0M, down $0.2M YoY, reflecting lower ONPATTRO royalty revenue
- Q3 operating loss $10.5M vs $8.7M loss YoY, operating margin -80.5% vs -67.2%
- Best program: IM-PROVE II, 53% (33/62) achieved functional cure or remained off NA therapy
- Cash and equivalents $264.2M at September 30, up from $18.0M; operating cash flow $225.7M
- Capital deployment: $230M share repurchase settled October 5; AB-101 development resumed after FDA clinical hold lifted
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward risks include clinical development and regulatory approval uncertainty
- Carried-forward risks include dependence on partnered product candidates and licensing arrangements
- Carried-forward risks include liquidity needs and potential financing requirements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arbutus Biopharma Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.